The US FDA has floated a variety of policies to combat the opioid epidemic in recent years, but addressing the crisis through opioid-sparing outcomes and the development of substitutable, non-opioid drugs may be the most difficult options to pursue following a series of votes from the agency's Anesthetic and Analgesic Drug Products Advisory Committee on Nov. 15.
Opioid-Sparing Regimens Face High Hurdles After US FDA Advisory Cmte.
Panelists felt the phrase "opioid sparing" was too broad, and contended that it is difficult to develop a non-opioid alternative without an opioid as an active comparator.
